Intra-Cellular Therapies EBITDA 2013-2022 | ITCI
Intra-Cellular Therapies annual and quarterly EBITDA history from 2013 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Intra-Cellular Therapies EBITDA for the quarter ending March 31, 2022 was $-0.077B, a 41.33% increase year-over-year.
- Intra-Cellular Therapies EBITDA for the twelve months ending March 31, 2022 was $-0.312B, a 31.88% increase year-over-year.
- Intra-Cellular Therapies 2021 annual EBITDA was $-0.289B, a 25.02% increase from 2020.
- Intra-Cellular Therapies 2020 annual EBITDA was $-0.231B, a 49.58% increase from 2019.
- Intra-Cellular Therapies 2019 annual EBITDA was $-0.155B, a 5.02% decline from 2018.
Intra-Cellular Therapies Annual EBITDA (Millions of US $) |
2021 |
$-289 |
2020 |
$-231 |
2019 |
$-155 |
2018 |
$-163 |
2017 |
$-102 |
2016 |
$-118 |
2015 |
$-105 |
2014 |
$-31 |
2013 |
$-26 |
2012 |
$-16 |
Intra-Cellular Therapies Quarterly EBITDA (Millions of US $) |
2022-03-31 |
$-77 |
2021-12-31 |
$-87 |
2021-09-30 |
$-79 |
2021-06-30 |
$-70 |
2021-03-31 |
$-54 |
2020-12-31 |
$-62 |
2020-09-30 |
$-56 |
2020-06-30 |
$-65 |
2020-03-31 |
$-49 |
2019-12-31 |
$-42 |
2019-09-30 |
$-36 |
2019-06-30 |
$-39 |
2019-03-31 |
$-37 |
2018-12-31 |
$-43 |
2018-09-30 |
$-44 |
2018-06-30 |
$-39 |
2018-03-31 |
$-37 |
2017-12-31 |
$-33 |
2017-09-30 |
$-24 |
2017-06-30 |
$-18 |
2017-03-31 |
$-28 |
2016-12-31 |
$-28 |
2016-09-30 |
$-30 |
2016-06-30 |
$-31 |
2016-03-31 |
$-28 |
2015-12-31 |
$-29 |
2015-09-30 |
$-32 |
2015-06-30 |
$-21 |
2015-03-31 |
$-22 |
2014-12-31 |
$-15 |
2014-09-30 |
$-6 |
2014-06-30 |
$-5 |
2014-03-31 |
$-5 |
2013-12-31 |
$-8 |
2013-09-30 |
$-5 |
2013-06-30 |
$-8 |
2013-03-31 |
$-5 |
2012-12-31 |
|
2012-09-30 |
$-2 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$5.373B |
$0.084B |
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|